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I am located in the Animal Biosciences and Biotechnology Laboratory of the Agricultural 
Research Service (ARS) in Beltsville, Maryland. Our lab falls under the purview of the 
national program or NP 101, which is food animal production, as well as NP 103, which 
is animal health. Within the lab we have five projects in three broad categories:
• Growth and reproduction,
• Health and alternatives to antibiotics, and 
• Development of genome-editing tools.
A partner on campus, Dr. Bhanu Telugu with the University of Maryland, works closely 
with us and is a major contributor to this presentation.
As we prepare projects, it’s important to recognize the interdependence of the health of 
all species and, furthermore, being part of the ARS, it’s important that whatever knowledge 
that we acquire and intervention strategies that we develop should have global application 
when and wherever possible.
Our research falls under the USDA’s priority Global Food Supply and Security and 
the focus is to maintain the efficient production of nutritious, affordable and safe food 
for human consumption. This will continue to be a priority, and, as we go forward, we 
anticipate challenges. For example, it is anticipated that, by 2050, there will be about a 
70 percent increase in the demand for animal protein, not only due to an increase in the 
global population but also due to increased individual wealth in less-developed countries, 
particularly as those people adopt a more western lifestyle, they will demand more meat 
in their diets. Also, it is predicted that, by 2050, a large increase in urbanization will have 
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occurred with decreases in rural populations, including the number of farmers. And it 
is expected that crop-farmland and animal-pasture “footprints” will be reduced in the 
next few decades.
Aside from challenges within the livestock-production system, another issue is animal 
disease as global travel increases. How do we mitigate current diseases as well as minimize 
the appearance of new diseases? We need to develop alternatives to antibiotics while fos-
tering growth promotion. Feed efficiency is another salient issue; we have very efficient 
animals now, but can we boost their efficiency further? Other issues are animal welfare 
and the interactions of animals with the environment and how these affect production.
Breeding and Selection
Selective breeding has been beneficial for the agricultural community with the produc-
tion of superior animals with desirable production traits including increased growth rate, 
increased feed efficiency, increased meat yield per animal as well as resistance to disease. 
On the other hand, frequently along with desirable traits, undesirable traits also segregate, 
such as the susceptibility to other diseases and, in litter-bearing species—particularly 
referring to swine—we’ve seen increased weight variability, and with attempts to increase 
muscle mass we may alter body structure, which has been known to affect reproductive 
capacity as well as raise animal-welfare concerns.
Another caveat for selective breeding is the length of time that it takes to achieve 
genotypic improvement; for cattle it can be about a quarter century. Selective breeding 
will continue, particularly considering increased genome information on animals, but 
the bigger question is whether there will be value in genetic engineering of livestock, par-
ticularly if we can guarantee precise targeting of an allele or quantitative trait nucleotides, 
improve traits and, therefore, produce healthy and safe animals.
Figure 1. Genetic engineering.
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Gene Targeting
Primarily, the ARS’s role in genetic engineering is development and refinement of tools. 
We are investigating technologies that utilize natural cellular mechanisms for genome 
repair that do not leave behind foreign DNA and precisely target genes of interest. And 
beyond development of tools, we seek opportunities for their implementation either 
through collaborative efforts or by passing on technologies to academia and industry. 
Like many present at this conference, our interests include TALENs and CRISPRs, in-
vestigating their utility primarily in swine and for addressing agricultural concerns such 
as animal well-being and zoonotic diseases.
We consider that there are two approaches for genetic engineering in farm animals 
(Figure 1). One is to modify the gene of interest in the genome of a somatic cell with 
either TALENs or CRISPRs and establish a cell line, and then use those cells for somatic 
nuclear cloning where you actually remove the genetically engineered (GE) nucleus fuse 
with an enucleated oocyte. Once the nucleus is in the oocyte, it is reprogrammed and a 
GE embryo generated. The second way is by direct modification of the gene of interest 
in the embryo genome again using TALENs and CRISPRs that are introduced directly 
into the embryo itself. 
TALENs
Figure 2 shows some recent reports of success in genetically engineering swine, cattle, and 
sheep by somatic cell nuclear transfer (SCNT) as well as direct embryo modification.
Initially, we tried to use the TALEN platform to target a gene that was in a safe-harbor 
site for knock-out; for our proof-of-concept experiment, we selected the prion gene. 
Again we were interested in trying to use direct swine-embryo modification using in vitro 
matured oocytes that were in vitro fertilized to generate embryos. We chose direct embryo 
modification over SCNT primarily because, with SCNT, the efficiency had been low and, 
in addition, quite often there are developmental issues with offspring.
Figure 2. Reported gene targeting of livestock.
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Briefly wrapping up our experiments with TALENs, at least in our hands only a low 
percentage of the embryos developed to the blastocyst stage. Additionally, when we evalu-
ated the sequences, many of our embryos had only a one-codon deletion. Accordingly, 
we moved on to CRISPRs because we had that technology operational at the same time, 
and, it seemed to work better in our hands.
CRISPRs
We chose the CRISPR-Cas9 system with which two approaches are possible, either 
through non-homologous end-joining, where you create an indel-mutation or, if you 
are interested in more-precise gene editing, you can adopt the homology-directed 
 recombination method.
In our first approach, as stated, we wanted to target the prion gene and, particularly, 
modify exon 3 in the prion gene, so we used the Cas9 nuclease with a T7 promoter for 
in vitro transcription (Figure 3). The construct also had the nuclear localization signal as 
well as green fluorescent protein (GFP) as a marker; the guide RNA had the T7 promoter 
as well. These constructs were in vitro transcribed and then the RNA was injected directly 
into one cell each of in vitro fertilized porcine embryos. Those embryos were then cultured 
in vitro and, at 24 hours post-injection, we found that about 80 percent were GFP-positive. 
Also, we were able to identify their localization—within the cells of the embryo—which 
was good for us. Furthermore, we were able to mature 30 percent of those embryos to 
the blastocyst stage, superior to our experience with the TALEN technique.
Figure 4 shows sequences of clones obtained from the embryos that were analyzed to 
determine whether we had bi-allelic or mono-allelic or mosaic modifications. The bot-
tom line is that we were successful in getting bi-allelic knock-outs or modifications in 
Figure 3. Gene knockouts in swine using the CRISPR/Cas NHEJ system.
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about 80 percent of the embryos. Both deletions and insertions were observed between 
embryos, and, in some cases, we saw embryos that were mosaic. Because one of the targets 
that we were eventually going after is actually a bigenic disease, we were also interested 
in seeing if we could knock out two genes at one time. In addition to the prion gene, 
we chose the zinc-finger bed containing six transcription factors; the take-home message 
here is that we were able to create deletions in both genes simultaneously in the same 
embryo. That was good proof-of-concept, indicating that we could go ahead and target 
our genome of interest.
The next approach was to see if we could actually insert into or directly edit a particular 
sequence within a gene. In this case, we decided to insert a short sequence into the Zbed6 
gene using the Cas nuclease with a guide tRNA, and a single-stranded DNA oligo that 
contained a loxP—i.e., the sequence that we wanted to insert—the construct was flanked 
on the 5’ end by an EcoR1 site (Figure 5). Again, the RNA constructs (nuclease and 
guide) plus the single-stranded DNA were injected into embryos, and, after we collected 
the embryos, a PCR was performed to see if we had actually been able to insert our short 
sequence. Figure 5 shows the banding patterns. The lower band is the wild-type allele 
that we expected. The upper band was of a size indicative of a 34-base-pair insertion. 
In addition, some embryos had the wild type and also had a lower band indicative of 
deletions in those embryos. The third pattern had a band of the same size as the wild 
type, but, because of its diffuse nature, we deduced that some other event had occurred 
in these embryos.
Figure 4. Successful single and double KOs.
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Figure 5. Gene-editing potential with HDR.
With the embryos that contained, what we thought was the loxP insertion, we did an 
EcoR1 digestion on the upper band; the allele that we thought contained loxP/EcoR1, 
and, sure enough, we were able to show that the EcoR1 site was inserted (Figure 6).
Figure 6. Confirmation of an EcoR1 site.
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Sequencing provided confirmation (Figure 7). We showed that we had the EcoR1 site 
plus the loxP gene inserted in a portion of the embryos, suggesting the ability to precisely 
target and modify a gene of interest; however, the sequence data also showed some random 
deletions and insertions. Although we need to work on this platform further, overall we 
were content that we were able to produce mono-allelic modifications.
Lastly, we were interested in determining if we could insert a transgene into a particular 
locus. In Figure 8, the upper schematic again shows the prion gene that we targeted for 
the introduction of a transgene into exon3. The middle schematic shows our proof-of-
Figure 7. Mono-allelic modifications with precise gene editing.
Figure 8. Gene insertion/replacement with Cas9 by homologous recombination.
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concept transgene, which consisted of a ubiquitin promoter, GFP as a marker and then the 
phosphoglycerate kinase and EM7 promoters that flanked the gene providing neomycin 
and kanamycin resistance. The entire transgene construct was about 7.6 kb. The bottom 
schematic shows the modified locus subsequent to the insertion of the transgene; oppos-
ing arrows denote where we had designed PCR primers in the 3’ end of the transgene 
construct and in the intron of the prion gene in order to amplify a 1,400-base-pair section 
to verify actual insertion of the transgene into the genome.
The construct along with the Cas9 guide RNA were injected into embryos, which we 
cultured to the blastocyst stage at day 7 (Figure 9) and, indeed, we were able to see GFP 
being expressed, indicating that we had successfully inserted our transgene. Furthermore, 
a PCR band appeared at the expected size subsequent to insertion of the transgene. 
Sequencing confirmed that many of the distinct embryos and the clones derived from 
those embryos also contained the transgene. On the other hand, we saw deletions in 
some of the embryos.
In Summary
We feel that we developed and successfully tested several CRISPR-based approaches for 
gene targeting in swine. We produced embryos and we were able to perform putative 
KOs using non-homologous end-joining and we plan to use this technology to address 
animal-welfare issues. We also feel that we can use the oligo-based insertion approaches 
to modify genes with homology-directed recombination, and we were also able to show 
that we could direct the targeting of expression cassettes into the genome of embryos as 
well.
On Going
We are probably a few years behind, but we are performing embryo transfers with our in 
vitro produced embryos in collaboration with the University of Maryland. We are trying 
to establish a dependable system to produce in vivo oocytes, so that we may actually go 
back and repeat this work, and then again try to refine the system by examining off-tar-
geting and increasing efficiency.
Even though we have not produced animals, pigs in particular have been produced 
with the CRISPR/Cas 9 system using the SCNT for CD163 or direct embryo modifica-
tion CD1D (Figure 9).
As an adjunct to our agricultural interests, when we focus on disease or welfare there is 
opportunity to study gene function particularly as more information is derived about the 
genome itself and as annotation is improved. There are also possibilities of dual benefit to 
agriculture and biomedicine where developmental issues and diseases are similar in swine 
and humans. Additionally, the pig has use as a model; for certain human diseases it is a 
better model than lab animals and it can also be applied to human transplantation.
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Figure 9. Use of the CRISPR/Cas9 system to produce genetically engineered pigs from 
in vitro-derived oocytes and embryos.
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